Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc Stock Forecast & Price Prediction

Live Alnylam Pharmaceuticals Inc Stock (ALNY) Price
$267.99

18

Ratings

  • Buy 13
  • Hold 4
  • Sell 1
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$267.99

P/E Ratio

-76.13

Volume Traded Today

$409,900

Dividend

Dividends not available for ALNY

52 Week High/low

287.55/141.98

Alnylam Pharmaceuticals Inc Market Cap

$34.61B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $ALNY ๐Ÿ›‘

Before you buy ALNY you'll want to see this list of ten stocks that have huge potential. Want to see if ALNY made the cut? Enter your email below

ALNY Summary

The Alnylam Pharmaceuticals Inc (ALNY) share price is expected to increase by 8.06% over the next year. This is based on calculating the average 12-month share price estimate provided by 18 stock analysts who have covered ALNY. Price targets range from $160.5 at the low end to $400 at the high end. The current analyst consensus for ALNY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

ALNY Analyst Ratings

About 18 Wall Street analysts have assigned ALNY 13 buy ratings, 4 hold ratings, and 1 sell ratings. This means that analysts expect Alnylam Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ALNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

ALNY stock forecast by analyst

These are the latest 20 analyst ratings of ALNY.

Analyst/Firm

Rating

Price Target

Change

Date

Luca Issi
RBC Capital

Outperform

$300

Reiterates

Sep 19, 2024
Olivia Brayer
Cantor Fitzgerald

Neutral

$220

Reiterates

Sep 9, 2024
Tazeen Ahmad
B of A Securities

Buy

$307

Maintains

Sep 4, 2024
Luca Issi
RBC Capital

Outperform

$300

Reiterates

Sep 4, 2024
Patrick Trucchio
HC Wainwright & Co.

Buy

$400

Reiterates

Aug 30, 2024
Jessica Fye
JP Morgan

Neutral

$280

Maintains

Aug 26, 2024
Patrick Trucchio
HC Wainwright & Co.

Buy

$400

Reiterates

Aug 20, 2024
Salveen Richter
Goldman Sachs

Buy

$370

Upgrade

Aug 16, 2024
Joseph Stringer
Needham

Buy

$320

Maintains

Aug 2, 2024
David Lebovitz
Citigroup

Buy

$342

Maintains

Aug 2, 2024
Salveen Richter
Goldman Sachs

Neutral

$198

Maintains

Aug 2, 2024
Tiago Fauth
Wells Fargo

Equal-Weight

$233

Maintains

Aug 2, 2024
Luca Issi
RBC Capital

Outperform

$300

Maintains

Aug 2, 2024
Whitney Ijem
Canaccord Genuity

Buy

$366

Maintains

Aug 2, 2024
Gena Wang
Barclays

Overweight

$295

Maintains

Aug 2, 2024
Gary Nachman
Raymond James

Outperform

$275

Maintains

Aug 2, 2024
Olivia Brayer
Cantor Fitzgerald

Neutral

$220

Maintains

Jul 22, 2024
Michael Ulz
Morgan Stanley

Equal-Weight

$255

Maintains

Jul 12, 2024
Whitney Ijem
Canaccord Genuity

Buy

$357

Maintains

Jul 8, 2024
Jessica Fye
JP Morgan

Neutral

$248

Maintains

Jul 3, 2024

ALNY Company Information

What They Do: Develops RNA interference-based therapeutics.

Business Model: The company focuses on discovering, developing, and commercializing novel therapeutics using RNA interference (RNAi) technology. It generates revenue through the sale of its marketed products, which target various diseases including hereditary amyloidosis, acute hepatic porphyria, and primary hyperoxaluria, among others. Additionally, Alnylam engages in strategic collaborations and licensing agreements with major pharmaceutical companies to enhance its research and development capabilities.

Other Information: Alnylam Pharmaceuticals has a diverse pipeline with various products in different stages of clinical trials, including treatments for Alzheimer's disease and NASH. The company has established partnerships with notable firms such as Regeneron and Roche, further strengthening its position in the biopharmaceutical market. Founded in 2002 and based in Cambridge, Massachusetts, Alnylam is a pioneer in RNAi therapeutics and continues to expand its impact in the healthcare sector.
ALNY
Alnylam Pharmaceuticals Inc (ALNY)

When did it IPO

2004

Staff Count

2,100

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Yvonne L. Greenstreet M.B.A., MBChB

Market Cap

$34.61B

Alnylam Pharmaceuticals Inc (ALNY) Financial Data

In 2023, ALNY generated $1.83B in revenue, which was a increase of 76.23% from the previous year. This can be seen as a signal that ALNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$492.9M

Revenue From 2021

$844.3M

71.31 %
From Previous Year

Revenue From 2022

$1.04B

22.88 %
From Previous Year

Revenue From 2023

$1.83B

76.23 %
From Previous Year
  • Revenue TTM $2.34B
  • Operating Margin TTM 7.4%
  • Gross profit TTM $1.52B
  • Return on assets TTM 1.7%
  • Return on equity TTM 199.5%
  • Profit Margin -3.1%
  • Book Value Per Share -0.02%
  • Market capitalisation $34.61B
  • Revenue for 2021 $844.3M
  • Revenue for 2022 $1.04B
  • Revenue for 2023 $1.83B
  • EPS this year (TTM) $-0.56

Alnylam Pharmaceuticals Inc (ALNY) Latest News

News Image

Tue, 01 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have shown performance metrics against their sector for the current year.

Why It Matters - Performance comparisons highlight how ALNY and CORT are faring relative to their sector, indicating market trends, investor sentiment, and potential investment opportunities.

News Image

Wed, 02 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Alnylam's revenues are increasing due to strong sales of Amvuttra and Givlaari, with positive progress in collaboration deals with RHHBY, NVS, and REGN.

Why It Matters - Strong sales of Amvuttra and Givlaari enhance Alnylam's revenue, while successful collaborations with major firms indicate growth potential and market confidence.

News Image

Sun, 29 Sep 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Alnylam Pharmaceuticals presented new data from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy at the HFSA Annual Scientific Meeting 2024.

Why It Matters - Alnylam Pharmaceuticals' new data on vutrisiran may enhance its market position in treating ATTR-CM, potentially impacting stock performance and investor sentiment toward the company.

News Image

Thu, 26 Sep 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Alnylam Pharmaceuticals will host a TTR Investor Day webcast on October 9, 2024, at 8:30 am ET. A replay will be available on their website within 48 hours post-event.

Why It Matters - Alnylam Pharmaceuticals' TTR Investor Day could reveal strategic insights and updates that may impact stock performance, attracting investor interest and influencing market sentiment.

News Image

Thu, 12 Sep 2024

Sentiment - POSITIVE

Source - MarketBeat

Summary - Alnylam Pharmaceuticals (NASDAQ: ALNY) stock has gained 100% over the past two years, driven by rising expectations for a market-disrupting heart treatment.

Why It Matters - Alnylam's 100% stock gain signals strong market confidence in its innovative heart treatment, potentially positioning it for significant future growth and increased investor returns.

News Image

Thu, 12 Sep 2024

Sentiment - NEUTRAL

Source - WSJ

Summary - Obscure diseases may present significant opportunities for drug companies, potentially leading to lucrative market prospects in niche therapeutic areas.

Why It Matters - Obscure diseases can lead to significant market potential for drug companies, potentially driving revenue growth and investment returns as they cater to unmet medical needs.

...

ALNY Frequently asked questions

The highest forecasted price for ALNY is $400 from Patrick Trucchio at HC Wainwright & Co..

The lowest forecasted price for ALNY is $160.5 from from

The ALNY analyst ratings consensus are 13 buy ratings, 4 hold ratings, and 1 sell ratings.